FDA asks for additional data to approve Evenity in US

Pharmaceutical companies Amgen and UCB have received a Complete Response Letter from the US Food and Drug Administration (FDA) for Evenity, a treatment for postmenopausal women with osteoporosis.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news